Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-11-21
2006-11-21
Saunders, David (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C435S007210, C435S007240, C435S007250, C436S543000, C530S333000, C530S402000
Reexamination Certificate
active
07138244
ABSTRACT:
Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when introduced into individuals, induce humoral anergy to the immunogen are disclosed. Accordingly, these conjugates are useful for treating antibody-mediated pathologies that are caused by foreign or self immunogens.
REFERENCES:
patent: 4191668 (1980-03-01), Katz
patent: 4220565 (1980-09-01), Katz
patent: 4388441 (1983-06-01), Katz
patent: 4430260 (1984-02-01), Lee et al.
patent: 4599231 (1986-07-01), Milich et al.
patent: 4650625 (1987-03-01), Pentlow
patent: 4650675 (1987-03-01), Borel et al.
patent: 4722899 (1988-02-01), Hamaoka
patent: 4803070 (1989-02-01), Cantrell et al.
patent: 4863740 (1989-09-01), Kissel et al.
patent: 4886782 (1989-12-01), Good et al.
patent: 4925787 (1990-05-01), Tanihara et al.
patent: 4950469 (1990-08-01), Katz
patent: 4950713 (1990-08-01), Katz
patent: 5017648 (1991-05-01), Katz
patent: 5102663 (1992-04-01), Livingston et al.
patent: 5126131 (1992-06-01), Dintzis et al.
patent: 5162515 (1992-11-01), Conrad et al.
patent: 5177188 (1993-01-01), Ginsberg et al.
patent: 5268454 (1993-12-01), Barstad et al.
patent: 5276013 (1994-01-01), Conrad et al.
patent: 5529922 (1996-06-01), Chapman et al.
patent: 5552391 (1996-09-01), Coutts et al.
patent: 5606047 (1997-02-01), Coutts et al.
patent: 5633395 (1997-05-01), Coutts et al.
patent: 5736146 (1998-04-01), Cohen et al.
patent: 5874409 (1999-02-01), Victoria et al.
patent: 6022544 (2000-02-01), Dintzis et al.
patent: 6060056 (2000-05-01), Coutts et al.
patent: 6207160 (2001-03-01), Victoria et al.
patent: 6340460 (2002-01-01), Dintzis et al.
patent: 6410775 (2002-06-01), Victoria et al.
patent: 6858210 (2005-02-01), Marquis et al.
patent: 2002/0082400 (2002-06-01), Coutts et al.
patent: 2002/0107389 (2002-08-01), Coutts et al.
patent: 2003/0103990 (2003-06-01), Coutts et al.
patent: 2003/0162953 (2003-08-01), Coutts et al.
patent: 2005/0004351 (2005-01-01), Marquis et al.
patent: 2005/0026856 (2005-02-01), Coutts et al.
patent: 2005/0031635 (2005-02-01), Coutts et al.
patent: WO 91/10426 (1991-07-01), None
patent: WO 91/12816 (1991-09-01), None
patent: WO 92/11029 (1992-07-01), None
patent: WO 92/11030 (1992-07-01), None
patent: WO 92/13558 (1992-08-01), None
patent: WO 93/02093 (1993-02-01), None
Abbas, A. et al. eds. (1991). “Lymphocyte Specificity and Activation,” Chapter 6In Cellular and Molecular Immunology. W.B. Saunders Company: Philadelphia, pp. 116-124.
Ada, G.L. (1987). “The Generation of Cellular vs. Humoral Immunity,” Chapter 3 inSynthetic Vaccines. Arnon, R., ed, CRC Press, Boca Raton, FL, pp. 25-37.
Alemany et al. (1987). “Phospho-dephospho-control by Insulin is Mimicked by a Phospho-oligosaccharide in Adipocytes,”Nature330:77-79.
Alvarez et al. (1991). “Transport in Isolated Rat Hepatocytes of the Phospho-oligosaccharide that Mimics Insulin Action,”Biochem J. 274:369-374.
Bach, J.F and J.P.Viard. (1990). “Hypothesis: Systemic Lupus Erythematosus as a Disease Secondary to Polyclonal Lymphocyte Activation,”Clin. Exp. Rheumatol. 8 (Suppl. 5):57-64.
Barstad et al. U.S. Appl. No. 10/957,198, filed on Oct. 1, 2004.
Bennett et al. (1992). “Idiotypic Mimicry of a Cell Surface DNA Receptor: Evidence for Anti-DNA Antibodies Being a Subset of Anti-DNA Receptor Antibodies,”Clin. Exp. Immunol. 90:428-433.
Bock et al. (1992). “Selection of Single-Stranded DNA Molecules that Bind and Inhibit Human Thrombin,”Nature355:564-566.
Bootsma et al. (1995). “Prevention of Relapses in Systemic Lupus Erythematosus,”Lancet345:1595-1599.
Borel, H. and T. Borel. (1990). “A Novel Technique to Link Either Proteins or Peptides to Gammaglobulin to Construct Tolerogens,”Journal of Immunological Methods126:159-168.
Borel, Y and H. Borel. (1988). “Oligonucleotide Linked to Human Gammaglobulin Specifically Diminishes Anti-DNA Antibody Formation in Cultured Lymphoid Cells from Patients with Systemic Lupus Erythematosus,”J. Clin. Invest. 82: 1901-1907.
Bradley, L.M. et al., (1980) “6.4 Antigen-Induced T Cell Proliferative Responses”Selected Methods In Cellular Immunology, Mishell, B.B. and S.M. Shiigi, eds., pp. 164-166.
Burke, J.M. and A. Berzal-Hemanz. (1993). “In VitroSelection and Evolution of RNA: Applications for Catalytic RNA , Molecular Recognition, and Drug Discovery,”FASEB J. 7:106-112.
Butterfield et al. (1981). “Immunotherapy with Short Ragweed Fraction A: D-glutamic Acid: D-lysine Polymer in Ragweed Hay Fever,”J. Allergy Clin. Immun. 67:272-278.
Chiller, J.M and W.O. Weigle. (1975). “Biography of a Tolerant State: Cellular Parameters of the Unresponsive State Induced in Adult Mice to Human Gamma Globulin,”J. Reticuloendothelial Soc. 17(3):180-186.
Coulson, E.J. and H. Stevens. (1961). “Some Observations on the Immunochemistry of Dextrans”J. Immunol. 86: 241-252.
Cwirla et al. (1990). “Peptides on Phage: A Vast Library of Peptides for Identifying Ligands,”PNAS USA87:6378-6382.
De Franco, A. (1989). “Tolerance: A Second Mechanism,”Nature342:340-341.
Devlin et al. (1990). “Random Peptide Libraries: A Source of Specific Protein Binding Molecules,”Science249:404-406.
Diamond et al. (1992). “The Role of Somatic Mutation in the Pathogenic Anti-DNA Response,”Ann. Rev. Immunol. 10:731-757.
Diamond, B. and M.D. Scharff. (1984). “Somatic Mutation of the T15 Heavy Chain Gives Rise to an Antibody with Autoantibody Specificity,”Proc. Natl. Acad. Sci. USA81:5841-5844.
Diner et al. (1979). “Carboxymethyl Cellulose, a Nonimmunogenic Hapten Carrier with Tolerogenic Properties,”J. Immunol. 122(5):1886-1891.
Dintzis et al. (1976). “Molecular Determinants of Immunogenicity: the Immunon Model of Immune Response,”Proc. Natl. Acad. Sci. USA73(10):3671-3675.
Dintzis et al. (1982). “Specific Cellular Stimulation in the Primary Immune Response: Experimental Test of a Quantized Model,”PNAS USA79:884-888.
Dintzis et al. (1983). “Studies on the Immunogenicity and Tolerogenicity of T-Independent Antigens,”J. Immunol. 131(5):2196-2203.
Dintzis et al. (1985). “Inhibition of Anti-DNP Antibody Formation by High Doses of DNP-Polyacrylamide Molecules: Effects of Hapten Density and Hapten Valence,”Journal of Immunology135(1):423-427.
Dintzis et al. (1989). “The Immunogenicity of Soluble Haptenated Polymers is Determined by Molecular Mass and Hapten Valence,”J. Immunol. 143(4):1239-1244.
Etlinger, H. and M. Chiller. (1977). “Induction of Tolerance in Athymic Mice with an Antigen Which is Highly Immunogenic in Euthymic Mice,”Cell. immunol. 33:297-308.
Finkelman, F.D. (1995). “Cross-linking of Membrane Immunoglobin D, in the Absence of T Cell Help, Kills Mature B CellsIn Vivo,” J. Exp. Med. 181:515-525.
Francis et al. (1988). “Peptides With Added T-cell Epitopes Can Overcome Genetic Restriction of the Immune Response,”Vaccines 88. Ginsberg, H., et al., eds., Cold Spring Harbor Laboratory, pp. 1-7.
Fulcher et al. (1994). “Whither the Anergic B-Cell?”Autoimmunity19:135-140.
Garrido, M.J. and C. Moreno. (1979). “The Use of Hapten-Polysaccharide Conjugates for the Induction of B-Cell Tolerance Involving IgE Responses,”Int. Archs. Allergy Appl: Immunol. 60:161-168.
Garvey et al. eds. (1977).Methods In Immunology, 3rd. ed., pp. 301-302.
Geysen et al. (1986). “The Delineation of Peptides Able to Mimic Assembled Epitopes,”Synthetic Peptides as Antigens, Ciba Symposium 119:130-149.
Golan, D.T and Y. Borel. (1971). “Nonantigenicity and Immunologic Tolerance: the Role of the Carrier in the Induction of Tolerance to the Hapten,”J. Exp Med. 134:1046-1061.
Goodnow, C.C. (1989). “Induction of Self-Tolerance in Mature Peripheral
Barstad Paul A.
Iverson Gilbert M.
La Jolla Pharmaceutical Company
Morrison & Foerster / LLP
Saunders David
LandOfFree
Composition for inducing humoral anergy to an immunogen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition for inducing humoral anergy to an immunogen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for inducing humoral anergy to an immunogen... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3675637